Guggenheim lowered the firm’s price target on Genfit (GNFT) to EUR 7 from EUR 9 and keeps a Buy rating on the shares after competitor CymaBay (CBAY) announced topline results from its Phase 3 trial of seladelpar in PBC. The firm believes “market leadership for CBAY, but perhaps not dominance over elafibranor, is not a guarantee,” and believes Ipsen’s initiation of the large 450 patient PBC outcomes trial “highlights its commitment to aggressively marketing elafibranor,” adding to its confidence that about EUR 180M in regulatory milestones will be paid to Genfit by the end of 2024, the analyst tells investors
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GNFT:
- Genfit publishes new data on clinical performance of NIS2+ in older patients
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue